Watching
GDRX · GoodRx Holdings, Inc.
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 23 October 2026; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A weekly close below $3.00, a round-number level 11.2% under the 14 October 2026 close of $3.38. A cut to the $790–805 million FY2026 revenue outlook, or another year-over-year fall in total revenue, would also break the case.
Not a pickResearch coverage at low conviction. A medium-or-higher call would open a pick on the scoreboard.
Catalyst (in 10 days)
How picks are graded →The thesis
GoodRx's recovery depends on Pharma Direct and subscriptions growing faster than its prescription-discount business shrinks. The third-quarter report, which MarketBeat estimates for about 3 November 2026, is the next real test. The shares closed at $3.38 on 14 October 2026, up from $3.27 on 1 October 2026. A weekly close below $3.00 would end the case.
The company has not changed the case since the last read. GoodRx has published no new results, guidance or SEC filings since early October. The only company headline in October was Benzinga's republication of the second-quarter call transcript on 5 October 2026. The 5 August 2026 results raised full-year 2026 revenue guidance to $790–805 million from $765–785 million. Second-quarter revenue was still about 1% lower than a year earlier at $200.4 million (GoodRx Q2 2026 press release, filed with the SEC).
The narrative is maturing. The pivot has been well known since August's guidance raise and the 3 September 2026 Companion Family Plan launch, and no new company news has arrived since. The rebound from the 1 October 2026 close shows short-term price strength, but nothing in the business has changed.
Bullish and bearish views on GoodRx Holdings, Inc.
The bull case on GoodRx Holdings, Inc. (GDRX), in brief: Growth lines are reaching scale. The bear case: The largest segment keeps shrinking.
Bull case
- Growth lines are reaching scale. In the second quarter of 2026, Pharma Direct revenue rose 76% from a year earlier to $61.6 million. Subscription revenue rose 39% to $28.5 million (GoodRx Q2 2026 results and 12 August 2026 call transcript).
- Guidance moved up in August. On 5 August 2026 GoodRx raised full-year revenue guidance to $790–805 million, above the $775.751 million analyst estimate cited by Benzinga.
- Cash generation improved. Second-quarter operating cash flow was $80.8 million, against $49.6 million a year earlier (12 August 2026 call transcript).
- Their Form 4 filed 26 August 2026 reported no remaining shares in those two funds.
- Analysts see room above the price. MarketBeat put the consensus price target at $4.23 on 14 October 2026, about 25% above the $3.38 close.
Bear case
- The largest segment keeps shrinking. Second-quarter prescription transactions revenue fell 26% year over year to $106.4 million. Monthly active consumers fell 12% to 5 million (12 August 2026 call transcript).
- Amazon competes on price. On 1 October 2026 the Spokesman-Review reported that Amazon's RxPass costs Prime members $5 per month for about 50 generic drugs. GoodRx's Companion plan costs $14.99 per month for more than 250 generics plus telehealth and other discounts.
- Debt exceeds cash. At the end of the second quarter, total debt was $492.5 million against $296.1 million of cash and equivalents (12 August 2026 call transcript).
- Insiders sold and none bought. MarketBeat counted $9,673,207 of insider sales and no insider purchases in the three months to 14 October 2026. Most of that came from Francisco Partners' late-August sales, which SEC Form 4 filings show were not made under a Rule 10b5-1 pre-arranged plan.
- Analyst targets are far apart. TipRanks recorded Bank of America's $2.65 target on 15 September 2026. Barclays kept an Underweight rating and a $4 target on 21 August 2026. Citigroup and TD Cowen raised their targets to $5 on 11 August 2026 (Benzinga).
Price setup
The shares closed at $3.38 on 14 October 2026, according to split- and dividend-adjusted daily closes. That is 18.4% below the 52-week high of $4.14 and 7.6% above the close three months earlier. The 14-day relative strength index (RSI, a 0–100 momentum gauge) was 51.4, a neutral reading.
After closes of $3.48 on 4 September 2026, $3.38 on 18 September 2026 and $3.27 on 1 October 2026, the price recovered to $3.38 by 14 October 2026. The $3.00 invalidation level is 11.2% below the latest close. The $3.44–3.51 range where Francisco Partners sold in late August is just above the current price.
There is little sign of crowding. MarketBeat reported short interest at 1.29% of the float, or 5.37 days to cover, as of 14 October 2026. No share issuance has been reported. The main crowding factor is the earnings date, which now likely falls inside the next 30 days.
Catalysts, next 30 days
- ~3 November 2026, est.: third-quarter 2026 results and call. MarketBeat lists this date as unconfirmed as of 14 October 2026. Last year GoodRx reported its third quarter on 4 November 2025 and announced that date on 8 October 2025. As of 15 October 2026 no 2026 date has been announced. The report will show whether total revenue returns to growth, whether the $790–805 million outlook holds, and how far prescription transactions fall from the second quarter's 26% decline.
What would change the view
The case breaks if the third-quarter report shows total revenue falling again year over year, or if GoodRx cuts the $790–805 million full-year revenue outlook. Either result would mean Pharma Direct and subscriptions are not yet replacing the lost discount revenue. Subscription revenue below the second quarter's $28.5 million, or monthly active consumers below 5 million, would indicate that Amazon's RxPass is pulling customers away.
On price, a weekly close below $3.00 would end the case. That round-number level sits 11.2% under the 14 October 2026 close.
The rating would move up if third-quarter revenue grows year over year and the full-year outlook is raised again. It would also move up if the prescription transactions decline narrows from 26%.
What it trades with
GoodRx trades mainly on its own quarterly results and guidance rather than on a sector theme. Its main competitive link is to Amazon's pharmacy pricing: the 1 October 2026 RxPass comparison sets the price ceiling for GoodRx's subscriptions. The prescription transactions line depends on fees from pharmacy benefit managers and on pharmacy traffic. Any policy or contract change affecting pharmacy benefit managers would hit that revenue directly.
Notes
- GoodRx guides annually ($790–805M revenue for FY2026) and gives no quarterly revenue guidance, so there are few checkpoints between reports.
- GDRX trades as Class A stock. The multi-class structure keeps voting control outside the traded Class A float.
- Prescription transactions was still the largest revenue line in Q2 2026 at $106.4M, even after falling 26% year over year.
Related · shared themes
HUM
Humana Inc.
Humana's 2027 Star Ratings put 95% of its Medicare Advantage members in 4-star-or-better plans, restoring 2028 bonus revenue; Humana's 6 November 2026 report tests whether 2026 medical costs stay inside guidance.
MCK
McKesson Corporation
McKesson's fast-growing oncology and specialty-drug business keeps lifting earnings above guidance; its 4 November 2026 report shows whether it raises the $44.20–$45.00 fiscal 2027 adjusted EPS outlook again.
LFST
LifeStance Health Group, Inc.
LifeStance Health can meet third-quarter adjusted-EBITDA guidance of $49–59 million without matching its $66.0 million second quarter. The 5 November 2026 report shows whether that holds and whether the $215–235 million full-year outlook rises.
STLN
Starling Oncology, Inc.
Starling Oncology's shift to capitated cancer-care contracts is lifting gross profit faster than revenue; the third-quarter 2026 report, expected around 12 November, shows whether adjusted EBITDA lands in the guided $500,000–$1.5 million range with full-year guidance intact.
See also · stocks to watch